ISAR-TRIPLE Antiplatelet Duration Algorithm
Clinical decision support
Review the post-PCI antithrombotic context. This tool summarizes evidence and guideline considerations; it does not calculate a validated treatment score.
guidelineEvidence
Complete the clinical context
Select the relevant fields and choose “Review strategy” to display the evidence summary and key considerations.
ISAR-TRIPLE compared 6 weeks with 6 months of clopidogrel within triple therapy after DES implantation. It did not establish a universal duration rule or a patient-level risk score.
Do not change or stop antiplatelet or anticoagulant treatment solely on the basis of this educational tool.
Clinical context and evidence
ISAR-TRIPLE was an open-label randomized trial of 614 patients receiving oral anticoagulation who underwent drug-eluting stent implantation. Participants received aspirin plus oral anticoagulation and were randomized to clopidogrel for 6 weeks or 6 months.
| Trial outcome at 9 months | 6 weeks | 6 months | Interpretation |
|---|---|---|---|
| Composite primary endpoint | 9.8% | 8.8% | HR 1.14; 95% CI 0.68–1.91; p=0.63. No significant difference. |
| Ischemic endpoint | 4.0% | 4.3% | No significant difference. |
| TIMI major bleeding | 5.3% | 4.0% | No significant difference in the overall comparison. |
How to interpret the trial
- The trial did not show superiority of 6 weeks over 6 months for its composite net clinical outcome.
- It compared specific clopidogrel durations in patients on aspirin and oral anticoagulation after DES implantation; it did not test every contemporary regimen or stent type.
- The study was conducted before many current DOAC-based and early aspirin-discontinuation strategies became standard. Its regimen should not be treated as a current universal default.
Contemporary guideline context
The 2025 ACC/AHA acute coronary syndromes guideline recommends that, in patients with ACS who require oral anticoagulation, aspirin generally be discontinued 1–4 weeks after PCI while continuing an oral anticoagulant and a P2Y₁₂ inhibitor (preferably clopidogrel). Individual procedural and ischemic considerations may affect the decision, including selected patients at high stent-thrombosis risk. Confirm the current applicable guideline and the patient's full clinical context before treatment decisions.
Practical review checklist
- Confirm the indication for anticoagulation and the correct anticoagulant/dose; mechanical valves generally require a vitamin K antagonist rather than a DOAC.
- Confirm PCI details, stent characteristics, procedural complexity, ACS presentation, and any history of stent thrombosis.
- Assess bleeding history, renal function, concomitant drugs, anemia, blood pressure, and modifiable bleeding risks.
- Document the intended aspirin stop date, P2Y₁₂ inhibitor plan, anticoagulation plan, and follow-up/reassessment arrangements.
- Consider gastroprotection when indicated and avoid unnecessary concomitant medicines that increase bleeding risk.
What this tool does not do
It does not estimate an individual probability of bleeding or ischemia, calculate a validated ISAR-TRIPLE score, prescribe a specific drug dose, or replace a clinician's assessment. HAS-BLED and CHA₂DS₂-VASc are displayed as context only and are not combined into a new score.
Selected references
Clinical notes
Document key findings and keep a structured record for your own reference.
My notes
Review, edit, or remove notes saved in this browser.
Report an issue
Your feedback helps us improve the reliability and usability of this clinical tool.